Accelerate Diagnostics
AXDX
AXDX was delisted on the 14th of May, 2025.
38 hedge funds and large institutions have $14.7M invested in Accelerate Diagnostics in 2023 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 6 increasing their positions, 12 reducing their positions, and 20 closing their positions.
18% less capital invested
Capital invested by funds: $18M → $14.7M (-$3.33M)
25% less funds holding
Funds holding: 51 → 38 (-13)
50% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 12
55% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 20
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CC
Cannell & Co
New York
|
+$772K |
| 2 |
GAM
Griffin Asset Management
New York
|
+$613K |
| 3 |
CI
Chartist Inc
Seal Beach,
California
|
+$451K |
| 4 |
TWA
TCI Wealth Advisors
Tucson,
Arizona
|
+$395K |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$237K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$99.7K |
| 2 |
OIM
Oracle Investment Management
Greenwich,
Connecticut
|
-$97.8K |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$52K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
-$44.5K |
| 5 |
CIBC Private Wealth Group
Atlanta,
Georgia
|
-$31.9K |
AXDX Hedge Fund Activity: Q3 2023 in Review
38 of the 6,310 institutional investors tracked by Wall St. Rank reported a position in Accelerate Diagnostics (AXDX) for Q3 2023, worth a combined $14.7M — down 18% from $18M a quarter earlier.
Sellers outnumbered buyers: 20 funds closed out of AXDX and 9 opened new positions — a net loss of 11 holders — while 12 trimmed existing stakes and 6 added.
The largest buyer was Cannell & Co, opening a new position worth an estimated $772K. The largest seller was Millennium Management, exiting entirely with an estimated $99.7K sold.
- 38 institutional investors held Accelerate Diagnostics (AXDX) as of Q3 2023, down from 51 in Q2 2023.
- Funds reported $14.7M of Accelerate Diagnostics stock for Q3 2023, down 18% quarter-over-quarter.
- 9 funds opened new Accelerate Diagnostics positions in Q3 2023 and 20 closed out, a net change of -11 holders.
- The largest Accelerate Diagnostics buyer in Q3 2023 was Cannell & Co, an estimated $772K added.
- The largest Accelerate Diagnostics seller in Q3 2023 was Millennium Management, an estimated $99.7K sold.
Based on aggregated 13F filings for Q3 2023.